Clinical trial of edaravone dexborneol in the treatment of patients with acute ischemic stroke
10.13699/j.cnki.1001-6821.2023.23.001
- VernacularTitle:依达拉奉右莰醇治疗急性缺血性脑卒中患者的临床研究
- Author:
Wen-Li LI
1
;
Tian-Tian ZHANG
;
Tian-Lun ZHENG
;
Ying-Hao HUO
;
Zhi-Qing ZHANG
Author Information
1. 河北医科大学第二医院药学部,河北石家庄 050000
- Keywords:
edaravone and dexborneol concentrated solution for injection;
acute ischemic stroke;
neurological function;
effectiveness;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2023;39(23):3347-3350
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of edaravone and dexborneol concentrated solution for injection in the treatment of patients with ischemic stroke.Methods Patients with acute ischemic stroke were divided into two groups,the control group was given conventional treatment,the treatment group was given edaravone and dexborneol concentrated solution for injection 15 mL on the basis of conventional treatment.The clinical efficacy of the two groups was compared.The National Institutes of Health stroke scale(NHISS)score was used to evaluate the neurological function of the patients,the modified RanKin scale(mRS)was used to evaluate the ability of daily living of the patients,and the adverse drug reactions during the treatment was observed.Results There were 63 cases in the control group and 75 cases in the treatment group.After treatment,the total effective rates of the treatment group and the control group were 85.33％(64 cases/75 cases)and 65.07％(41 cases/63 cases),and the difference was statistically significant(P＜0.05).After treatment,the differences of NHISS score before and after treatment in the treatment group and the control group were(2.11±1.01)and(0.99±0.68)points;the differences of mRS score were(0.96±0.57)and(0.63±0.41)points,and the differences were statistically significant(P＜0.01,P＜0.05).The adverse drug reactions in the two groups were nausea and vomiting,abnormal liver and kidney function.The total incidences of adverse drug reactions in the treatment group and control group were 2.67％and 6.35％,and the difference was not statistically significant(P＞0.05).Conclusion Edaravone and dexborneol concentrated solution for injection can improve the therapeutic effect of acute ischemic stroke without increasing the incidence of adverse drug reactions.
